ERBB2 and invasive ductal breast carcinoma: Regarding the histology, 90.91% of patients were infiltrating ductal carcinoma, 80% ER-positive, 67.27% PR-positive, 61.82% HER2-negative, and 12.73% triple-negative breast cancer.